Navigation Links
DelMar Pharmaceuticals Presents Interim Phase 1/2 Clinical Data for VAL-083 in Glioblastoma at Society for Neuro-Oncology Annual Meeting
Date:11/22/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 22, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco.  Enrollment in the first four cohorts of the VAL-083 trial has been completed with no significant adverse events or dose limiting toxicity (DLT) observed.  Twenty five percent of patients evaluated in Cohorts 1-3 exhibited stable disease or tumor-regression and improved disease symptoms.  Evaluation and clinical observations of Cohort 4 is ongoing. 

"The fact that we are seeing evidence of clinical activity against refractory GBM at this stage is very promising," said Jeffrey Bacha, president & CEO of DelMar Pharmaceuticals. "VAL-083 is safe and well-tolerated by patients at the doses tested to date, and based on historical data, we anticipate seeing stronger patient benefit and tumor responses as we achieve higher doses."

DelMar's Phase 1/2 study is an open-label, single arm dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of VAL-083 in patients with recurrent GBM.  Patients in the trial must have been previously treated for GBM with surgery and/or radiation and must have failed both Avastin® and Temodar®, unless either or both are contra-indicated. 

Details of the presentation:- Maximum tolerated dose (MTD) has not yet been reached. 

- Enrollment of Cohort 5 (20mg/m2) is expected in December 2013, subject to complet
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
2. DelMar Pharmaceuticals Gives Quarterly Shareholder Update
3. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
4. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
5. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
6. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
7. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
9. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
10. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
11. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... 2011 As NFL coaches and players face a dramatically ... team,s preparation will be gaining a competitive edge as it ... Today, Polar USA and the Atlanta Falcons announced that the ... Heart Rate Training System" of the Atlanta Falcons. ...
... CINCINNATI, Sept. 7, 2011 HealthWarehouse.com, Inc. (OTC: HEWA) ... that Lalit Dhadphale, president and CEO of HealthWarehouse.com, will ...  The presentation will begin at 10:00 a.m. Eastern Time ... invited to listen to a live web cast of ...
Cached Medicine Technology:Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 2Polar Team2 Pro Set Solution Is Official Heart Rate Training System for the Atlanta Falcons 3
(Date:12/26/2014)... 26, 2014 DW-InductionHeating.com (DaWei Induction Heating ... researching and developing, producing and marketing of a series ... business announces their new series of induction brazing ... the company, induction brazing refers to the ... filler material and heat. The manager says that there ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... Pharmaceutical Marketing Industry Due to New PhRMA Marketing ... Pharmaceutical marketers are taking on the 2009 ... a unique marketing company whose integrated engagement solutions ... sector. In the past two years the company ...
... Disease Depend on Plasma DonationANNAPOLIS, Md., Jan. 6 Kawasaki ... between the ages of two and five and is ... in the United States according to the American Heart ... globulin (IVIG), a plasma-derived therapy that replaces vital missing ...
... flow leader positioned for expanding role of patient flow ... has been helping its clients, now more than 700 ... The need to increase capacity and improve patient ... of U.S. hospitals have postponed building and expansion plans ...
... Music Organization Will Offer "The Prevention Plan(TM)" Health ... Preventive Medicine(R), the leader in disease prevention, today ... performing right organization that represents more than 375,000 ... Prevention Plan(TM) to its members at a discount. ...
... N.C., Jan. 6 Compass Group North America ... of Harwood Heights,Illinois-based KIMCO Corporation, a provider of ... sector. Through the acquisition, KIMCO,becomes a wholly owned ... a division of Compass Group North America focused ...
... Rising Medical Solutions, Inc. (Rising), a,leading medical ... Company will provide Medical Data Call services for ... data to the National Council on,Compensation Insurance, Inc. ... http://www.newscom.com/cgi-bin/prnh/20080206/AQW030LOGO-b ) , ...
Cached Medicine News:Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 2Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 3Health News:Kawasaki Disease Treated with Plasma-Derived Therapy 2Health News:TeleTracking Technologies to Focus on Growth 2Health News:TeleTracking Technologies to Focus on Growth 3Health News:U.S. Preventive Medicine(R) Strikes a Note with Broadcast Music, Inc. 2Health News:Compass Group North America Acquires KIMCO Corporation 2Health News:Rising Medical Solutions to Provide NCCI Medical Data Call Services 2
... one of our highly featured models. This model has ... target using the mouse to have the patient look ... allow the unit to photograph a particular area on ... after you have taken the picture you can ascertain ...
... laser combines excellent cutting, ablation and ... procedures. It is also extremely effective ... stones of all compositions, making it ... its laser light is transmitted through ...
... Thanks to the progress and perfecting ... techniques have acquired a more strategic role ... technology in this sector has certainly contributed ... various urological pathologies that are becoming more ...
... PhotoLightFACIAL facial skin treatment, vascular ... Incorporates a wide range ... multiple hand pieces and large ... the most flexibility. Compact ...
Medicine Products: